Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
تم التحليل: 2026-05-08التحديث التالي: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
السعر
$378.06
▼ -38.07 (-10.07%)
القيمة العادلة
$340
$340–$450
التصنيف
تخفيض
confidence 88/100
إمكانية الصعود
-10.1%
upside to fair value
هامش الأمان
$288.99
buy below · 15%
القيمة السوقية
$343.3B
P/E fwd 18.2
المصدر الإنجليزيAR
يتم عرض المصدر الإنجليزي أثناء الترجمة
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.

§1 الملخص التنفيذي

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 السيناريو الهبوطي

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

كيف يمكن أن تفشل هذه الأطروحة

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
إشارات الإنذار المبكر للمراقبة
المقياسالحاليحد التشغيل
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 التاريخ المالي

بيان الدخل — آخر ستة فترات
البندT−0T−1T−2T−3T−4معدل النمو السنوي المركب
الفترة2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
الإيرادات$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
إجمالي الربح$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
الدخل التشغيلي$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
صافي الدخل$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
EPS (مخفف)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
البحث والتطوير
المصاريف الإدارية والبيعية

درجات الجودة

درجة Piotroski F
6 / 9
مركب جودة 0–9
درجة Altman Z
2.97
مخاطر الإفلاس (>3 آمن)
OCF / صافي الدخل
1.63×
>1 يشير إلى جودة عالية للأرباح
حد جودة المحاسبة
Pass
حد معدل حسب القطاع
ROIC
8.6%
العائد على رأس المال المستثمر
القسم 3

Numbers analysis

تخصيص رأس المال

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

المشتركون الأفراد — من §4 فصاعداً11 قسماً إضافياً

اقرأ التحليل الكامل — 11 قسماً إضافياً.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

تقرير كامل لكل سهم مغطى
أرشيف تصنيفات 24 شهراً
إيجازات قائمة المراقبة + تنبيهات تغيير التصنيف
تصدير PDF + DOCX بأي لغة
ابدأ تجربة مجانية
إلغاء في أي وقت.
FAQ

UNH — frequently asked questions

  1. Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care